A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent

BACKGROUND Prostate‐specific membrane antigen (PSMA) remains an active target for imaging and therapeutic applications for prostate cancer. METHODS In the present study, an irreversible phosphoramidate inhibitor, CTT‐54 (IC50 = 14 nM), has been modified to deliver 99mTc‐(CO)3‐DTPA as a SPECT imaging...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Prostate 2012-06, Vol.72 (8), p.904-912
Hauptverfasser:	Nedrow-Byers, Jessie R., Jabbes, Mohamed, Jewett, Cayla, Ganguly, Tanushree, He, Haiyang, Liu, Tiancheng, Benny, Paul, Bryan, Jeffrey N., Berkman, Clifford E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - metabolism Adenocarcinoma - pathology Amides - metabolism Animals Biological and medical sciences Cell Line, Tumor Gynecology. Andrology. Obstetrics Humans In Vitro Techniques Male Male genital diseases Medical sciences Mice Mice, Nude Nephrology. Urinary tract diseases Pentetic Acid - metabolism Phosphoric Acids - metabolism prostate cancer Prostate-Specific Antigen - metabolism Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology PSMA radioimaging Sensitivity and Specificity Technetium - metabolism Time Factors Tomography, Emission-Computed, Single-Photon - methods Transplantation, Heterologous Tumors Tumors of the urinary system Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!